Short amyloid-β immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer's disease immunotherapy

NeuroReport

Volumn 23, Issue 15, 2012, Pages 879-884

  Guan, Xiaoying ^a   Zou, Juntao ^a   Gu, Huaiyu ^a   Yao, Zhibin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; amyloid 1 15; junctional epitopes; spacer

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; UNCLASSIFIED DRUG; VACCINE;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; TANDEM REPEAT; TH2 CELL;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; EPITOPES; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MICE;

EID: 84866323602     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328358a044     Document Type: Article

References (20)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741-766. (Pubitemid 32267077)
2. Wisniewski T, Boutajangout A. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct 2009; 214:201-218.
3. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15:505-514. (Pubitemid 36432403)
4. Bard F. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003; 100:2023-2028. (Pubitemid 36254567)
5. Sigurdsson EM. An attenuated immune response is sufficient to enhance cognition in an alzheimer's disease mouse model immunized with amyloid-derivatives. J Neurosci 2004; 24:6277-6282. (Pubitemid 38944217)
6. Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, et al. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2005; 2:28.
7. Seabrook TJ, Jiang L, Thomas K, Lemere CA. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. J Neuroinflammation 2006; 3:14.
8. Leverone J. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting. Vaccine 2003; 21:2197-2206.
9. Liu Z, Wang Z, Chen YH. Predefined spacers between epitopes on a recombinant epitope-peptide impacted epitope-specific antibody response. Immunoly Lett 2005; 97:41-45. (Pubitemid 40038853)
10. Tian L, Wang HN Lu D, Zhang YF, Wang T, Kang RM. The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens. Biochem Biophys Res Commun 2008; 377:221-225.
11. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 1997; 158:3947-3958. (Pubitemid 127488755)
12. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-1586.
13. Pala P, Hussell T, Openshaw PJ. Flow cytometric measurement of intracellular cytokines. J Immunol Methods 2000; 243:107-124.
14. Tuominen-Gustafsson H, Penttinen M, Hytonen J, Viljanen MK. Use of CFSE staining of borreliae in studies on the interaction between borreliae and human neutrophils. BMC Microbiol 2006; 6:92.
15. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002; 168:5499-5506. (Pubitemid 34556128)
16. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001; 166:5366-5373. (Pubitemid 32374155)
17. Shi JQ, Chen J, Wang BR, Zhu YW, Xu Y, Wang J, et al. Short amyloid-beta immunogens show strong immunogenicity and avoid stimulating pro-inflammatory pathways in bone marrow-derived dendritic cells from C57BL/6J mice in vitro. Peptides 2011; 32:1617-1625.
18. Li H, Zou J, Yao Z, Yu J, Wang H, Xu J. Tetravalent Ab1-15 vaccine reduces TCR-positive cell infiltration and up-regulates p75 in Tg2576 brains compared to Ab42 vaccine. J Neuroimmunol 2010; 219:8-16.
19. Zou J, Yao Z, Zhang G, Wang H, Xu J, Yew DT, et al. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Ab1-15 reduces Ab burden and behavioral impairment without Ab-specific T cell response. J Neurol Sci 2008; 272:87-98.
20. Guruprasad K, Rajkumar S. Beta-and gamma-turns in proteins revisited: a new set of amino acid turn-type dependent positional preferences and potentials. J Biosci 2000; 25:143-156.